Third prize: The role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma

Journal of Endourology

Volumn 25, Issue 3, 2011, Pages 377-384

  Raymundo, Eliza M ^a,b   Lipkin, Michael E ^a   Bañez, Lionel B ^a   Mancini, John G ^a   Zilberman, Dorit E ^a   Preminger, Glenn M ^a   Inman, Brant A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PHILIPPINE GENERAL HOSPITAL   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; ENDOSCOPIC SURGERY; FEMALE; FISHER EXACT TEST; FOLLOW UP; HAZARD RATIO; HUMAN; LENGTH OF STAY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHRON SPARING SURGERY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANK SUM TEST; RECURRENT DISEASE; SEX DIFFERENCE; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AWARDS AND PRIZES; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; ENDOSCOPY; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRECTOMY; NEPHRONS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; URINARY BLADDER NEOPLASMS;

EID: 79952632722     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2010.0276     Document Type: Article

References (53)

1. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: Incidence and survival during the last two decades. J Urol 2000;154:1523-1525.
2. Png KS, Lim EKW, Chong KT, et al. Prognostic factors for upper tract transitional cell carcinoma: A retrospective review of 66 patients. Asian J Surg 2008;31:20-24.
3. Murta CB, Antunes AA, Dall'Oglio MF, et al. Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma. Clinics 2008;63:223-228.
4. Tawfiek ER, Baglesy DH. Upper-tract transitional cell carcinoma. Urology 1997;50:321-329. (Pubitemid 27428106)
5. Andersen JR, Kristensen JK. Ureteroscopic management of transitional cell tumors. Scand J Urol Nephrol 1994;28:153-157. (Pubitemid 24205373)
6. Williams SK, Denton KJ, Minervini A, et al. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J Endourol 2008;22:71-77.
7. Guarnizo E, Pavlovich PC, Seiba M, et al. Ureteroscopic biopsy of upper tract urothelial carcinoma: Improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol 2000;163:52-55.
8. Vikram R, Chandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: Part 2, upper urinary tract. Am J Radiol 2009;192:1488-1493.
9. Huffman JL, Bagley DH, Lyon ES, et al. Endoscopic diagnosis and treatment of upper-tract urothelial tumors-a preliminary report. Cancer 1985;55:1422-1428. (Pubitemid 15143425)
10. Rastinehad AR, Smith AD. Bacillus Calmette-Guerin for upper tract urothelial cancer: Is there a role? J Endourol 2009;23:563-568.
11. Jarrett TW, Sweetser PM, Weiss GH, Smith AD. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-Year experience. J Urol 1995;154:1629-1635.
12. Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: Results from the upper tract urothelial carcinoma collaboration. J Urol 2009;182:900-906.
13. Katz MH, Lee MW, Gupta M. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-ά2B. J Endourol 2007;21:374-377. (Pubitemid 46764201)
14. Soderdahl DW, Fabrizio MD, Rahman NU, et al. Endoscopic treatment of upper tract transitional cell carcinoma. Urol Oncol 2005;23:114-122. (Pubitemid 40616302)
15. Iwaszko MR, Krambeck AE. Conservative management of upper tract transitional cell carcinoma. Indian J Urol 2008; 24:159-163.
16. Martinez-Pineiro JA, Matres MJC, Martinez-Pineiro L. Endourological treatment of upper tract urothelial carcinomas: Analysis of a series of 59 tumors. J Urol 1996;156:377-385. (Pubitemid 126445346)
17. Guinan P, Vogelzang NJ, Randazzo R, et al. Renals pelvic cancer: A review of 611 patients treated in Illinois 1975-1985. Urology 1992;40:393-399.
18. Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A populationbased study of 2299 patients. Eur J Cancer 2009;45:3291-3297.
19. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: A review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol 2008;15:127-139. (Pubitemid 351591496)
20. Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 2000;27:739-750.
21. Simone G, Papalia R, Loreta A, et al. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int 2008;103:1052-1057.
22. Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: A multi-institutional analysis of 1363 patients. BJU Int 2008;103:307-311.
23. Iwaszko MR. Conservative management of upper tract transitional cell carcinoma. Indian J Urol 2008;24:159-163.
24. Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette- Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 2000;38:701-704.
25. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer 2009;115:1224-1233.
26. Novara G, De Marco V, Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract multi-institutional dataset from 3 European centers. Cancer 2007;110:1715-1721.
27. Gill IS, Sung GT, Hobart MG, et al. Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: The Cleveland Clinic experience. J Urol 2000;164: 1513-1522.
28. Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughn ED, Jr., eds. Campbell's Urology, 8th edition, Vol. 4. Philadelphia: Saunders-Elsevier, 1998, pp. 2732-2784.
29. Clark PE, Streem SB, Geisinger MA. 13-Year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol 1999;161:772-776. (Pubitemid 29422364)
30. Chen GL, Bagley DH. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 2000;164:1173-1176.
31. Keeley FX, Bibbo M, Bagley DH. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 1997;157:1560-1565. (Pubitemid 27171724)
32. Keeley FX, Bagley DH. Mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol 1997;158:2074-2077. (Pubitemid 27481330)
33. Greco F, Wagner S, Hoda RM, et al. Laparoscopic vs open radical nephroureterectomy for upper urinary tract urothelial cancer: Oncological outcomes and 5-year follow-up. BJU Int 2009;104:1274-1278.
34. Tan LB, Chiang LL, Cheng KI, et al. Transitional cell carcinomas of the renal pelvis and the ureter: A comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU Int 2009;103:312-315.
35. Smith AD, Orihuel E, Crowley AR. Percutaneous management of renal pelvic tumors: A treatment option in selected cases. J Urol 1987;137:852-856. (Pubitemid 17074875)
36. Ponchietti R, Neri B, DiLoro F, Raugei A. Endoluminal instillation of epidoxorubicin as adjuvant treatment for upper urinary tract urothelial tumours. Anticancer Res 1996;16:537-540. (Pubitemid 126497999)
37. Eastham JA, Huffman JL. Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol 1993;150:324-325. (Pubitemid 23215861)
38. Montanari E, Del Nero A, Bernardini P, et al. Percutaneous therapy of low stage and grade urothelial neoplasia: long-term follow up. Arch Ital Urol Androl 2005;77:211-214. (Abstract). (Pubitemid 43067286)
39. Orihuela E, Smith AD. Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1988;15:425-431.
40. Studer U, Casanova G, Kraft R, Zing E. Percutaneous BCG perfusion of the upper urinary tract for carcinoma-in-situ. J Urol 1989;142:975-977. (Pubitemid 19250744)
41. Chew BH, Pautler SE, Denstedt JD. Percutaneous management of upper-tract transitional cell carcinoma. J Endourol 2005;19:658-663. (Pubitemid 41129778)
42. Sharpe JR, Duffy G, Chin JL. Intrarenal BCG therapy for uppr urinary tract carcinoma in situ. J Urol 1993;149:457-460. (Pubitemid 23094029)
43. Thalmann GN, Markwalder R, Walter B, Studer UE. Longterm experience with Bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002;168:1381-1385. (Pubitemid 35034127)
44. Yokogi H, Wada Y, Mizutani M, et al. Bacillus Calmette- Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. BJU 1996;77:676-679.
45. Maulard-Durdux C, Dufur B, Hennequin C, et al. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: No impact on survival? J Urol 1996;155:115-117. (Pubitemid 126426443)
46. Sylvester RJ, Oosterlinck W, Van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta-T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 2004;171:186-190.
47. Divrik RT, Yildirum U, Zorlu F, Ö zen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial. J Urol 2006;175:1641-1644.
48. Clauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology 2010;76:658-663.
49. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102:1111-1114.
50. Naselli A, Introni C, Bertolotto F, et al. Narrow band imaging f detecting residual=recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer. BJU Int 2009;105:208-211.
51. Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int 2007;101:705-706.
52. Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-Year results of prospective randomized study. Urology 2007;69:675-679. (Pubitemid 46574917)
53. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using Hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 2005;174:862-866. (Pubitemid 41140613)